Last reviewed · How we verify
Obinutuzumab administration
Obinutuzumab is a monoclonal antibody that binds to CD20 on B cells, triggering their destruction through antibody-dependent cellular cytotoxicity and direct cell death.
Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody developed by Genentech/Roche and administered intravenously for B-cell malignancies. The drug binds to CD20 antigen on B-cell surfaces, triggering direct cell death through enhanced antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), with superior direct cell death compared to rituximab. Approved by the FDA in 2013 for chronic lymphocytic leukemia (CLL) and follicular lymphoma, obinutuzumab has expanded into multiple combination regimens including venetoclax, ibrutinib, and targeted therapies across CLL, follicular lymphoma, marginal zone lymphoma, and diffuse large B-cell lymphoma. The drug generated approximately $1.2B in annual revenue (2023) and maintains significant market share in front-line CLL treatment, particularly in time-limited combination therapy paradigms. Current Phase 3 pipeline includes studies combining obinutuzumab with Bcl-2 inhibitors (sonrotoclax), BTK inhibitors (zanubrutinib), and venetoclax-based regimens, positioning it as a cornerstone agent in evolving B-cell lymphoma treatment algorithms.
At a glance
| Generic name | Obinutuzumab administration |
|---|---|
| Also known as | GAZYVARO® administration |
| Sponsor | Radboud University Medical Center |
| Drug class | Anti-CD20 monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Obinutuzumab targets CD20, a surface antigen expressed on B lymphocytes. Upon binding, it activates the immune system to eliminate B cells through multiple mechanisms including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and direct induction of apoptosis. This B-cell depletion is therapeutically beneficial in B-cell malignancies and certain autoimmune conditions.
Approved indications
- Chronic lymphocytic leukemia (CLL)
- Follicular lymphoma
- Diffuse large B-cell lymphoma (DLBCL)
Common side effects
- Infusion reactions
- Neutropenia
- Thrombocytopenia
- Anemia
- Infections
- Fatigue
- Nausea